HSC/UTSA collaborate with Merck to develop vaccine

The Health Science Center and the University of Texas at San Antonio (UTSA) announced an exclusive license and sponsored research agreement with Merck & Co. Inc. to develop a vaccine for chlamydia, targeting the common sexually transmitted bacterium Chlamydia trachomatis. “The Health Science Center strives not only to make discoveries that improve the quality of life but also to make sure these breakthroughs are rapidly disseminated through the commercialization process so they can help as many people as possible,” said Brian Herman, Ph.D., vice president for research at the Health Science Center. “We welcome this opportunity to further advance our already successful collaboration with UTSA.”